<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pharmacogenomics</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmacogenomics</journal-id>
<journal-id journal-id-type="publisher-id">PGS</journal-id>
<journal-title-group>
<journal-title>Pharmacogenomics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1462-2416</issn>
<issn pub-type="epub">1744-8042</issn>
<publisher>
<publisher-name>Future Medicine Ltd</publisher-name>
<publisher-loc>London, UK</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28346058</article-id>
<article-id pub-id-type="pmc">5558539</article-id>
<article-id pub-id-type="doi">10.2217/pgs-2016-0193</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models</article-title>
<alt-title alt-title-type="running-head">Rinker &amp; Mulholland</alt-title>
<alt-title alt-title-type="running-head">Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Rinker</surname>
<given-names>Jennifer A</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff1"></xref>
<xref ref-type="aff" rid="aff2"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mulholland</surname>
<given-names>Patrick J</given-names>
</name>
<xref ref-type="corresp" rid="C0001">*</xref>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff1"></xref>
<xref ref-type="aff" rid="aff2"></xref>
</contrib>
<aff id="aff1">
<label>1</label>Department of Neuroscience, Medical University of South Carolina, Charleston, SC 29425, USA</aff>
<aff id="aff2">
<label>2</label>Department of Psychiatry &amp; Behavioral Sciences, Charleston Alcohol Research Center, Addiction Sciences Division, Medical University of South Carolina, Charleston, SC 29425, USA</aff>
</contrib-group>
<author-notes>
<corresp id="C0001">*Author for correspondence: <email xlink:href="mailto:mulholl@musc.edu">mulholl@musc.edu</email></corresp>
<fn fn-type="COI-statement">
<p>
<bold>Financial &amp; competing interests disclosure</bold>
</p>
<p>This work was funded by NIH grants AA020930 and AA023288. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p>
<p>No writing assistance was utilized in the production of this manuscript.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>3</month>
<year>2017</year>
</pub-date>
<volume>18</volume>
<issue>6</issue>
<fpage>555</fpage>
<lpage>570</lpage>
<history>
<date date-type="received">
<day>08</day>
<month>12</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>1</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© 2017 Future Medicine Ltd</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="pgs-18-555.pdf" xlink:type="simple"></self-uri>
<abstract>
<p>Inherited genetic variants contribute to risk factors for developing an alcohol use disorder, and polymorphisms may inform precision medicine strategies for treating alcohol addiction. Targeting genetic mutations linked to alcohol phenotypes has provided promising initial evidence for reducing relapse rates in alcoholics. Although successful in some studies, there are conflicting findings and the reports of adverse effects may ultimately limit their clinical utility, suggesting that novel pharmacogenetic targets are necessary to advance precision medicine approaches. Here, we describe promising novel genetic variants derived from preclinical models of alcohol consumption and dependence that may uncover disease mechanisms that drive uncontrolled drinking and identify novel pharmacogenetic targets that facilitate therapeutic intervention for the treatment of alcohol use disorder.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords: </title>
<kwd>alcohol use disorder</kwd>
<kwd>K<sup>+</sup> channels</kwd>
<kwd>neuroimmune genes</kwd>
<kwd>pharmacogenetics</kwd>
<kwd>preclinical models</kwd>
<kwd>RAS signaling</kwd>
<kwd>tachykinins</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>